Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (June 2021)
25 slides from Imugene's investor presentation, Jun 11, 2021
Slide 1: Imugene
For personal use only ASX: IMU IMUGENE 11 June 2021
Slide 2: Disclaimer
Disclaimer For personal use only 1. The information in this presentation does not constitute personal investment 4. Neither the Company nor any of its directors, officers, employees, advisers, advice. The presentation is not intended to be comprehensive or provide all associated persons or subsidiar
Slide 3: Introduction to Imugene
Introduction to Imugene 2019 Completed the For personal use only acquisition of a prolific 2 017 oncolytic virus from Imugene is a biotech company HER-Vaxx, our HER-2 City of Hope invented by targeted B Cell Dr Yuman Fong headquartered in Australia and Immunotherapy publicly traded on the Australian
Slide 4: Investment Highlights
Investment Highlights For personal use only • Three novel technology platforms: Oncolytic virotherapies, onCARlytics in cellular therapy and B-Cell activating immunotherapies • B-Cell Technologies: HER-Vaxx Phase 2 in gastric cancer and PD1-Vaxx in NSCLC • CF33 Oncolytic Virotherapies: 2 Phase 1 Cli
Slide 5: onCARlytics
onCARlytics Acquisition For personal use only Worldwide exclusive license The four FDA approved CD19 Compelling pre-clinical activity OnCARlytics Phase 1 study to CAR T drugs only work in in TNBC, colorectal, pancreatic, commence in 2022 to novel technology which blood cancers- solid tumours prostat
Slide 6: Three Novel Technology Platforms
Three Novel Technology Platforms For personal use only onCARlytics CF33 Oncolytic Virus B Cell Immunotherapy CHECKvacc VAXINIA CF33-CD19 CAR T Combination Therapy HER-Vaxx PD1-Vaxx “Armed” Virus Parental Virus B-Vaxx, PDL1-Vaxx, LAG3-Vaxx, TIM3-Vaxx, VEGF-Vaxx, CTLA4-Vaxx etc 6
Slide 7: Imugene's Deep Pipeline
Imugene’s Deep Pipeline Clinical Clinical development development Intellectual For personal use only Pre-clinical Phase 1 Phase 2 Key Data / Results Property • Compelling pre-clinical activity in multiple cancers when combining onCARlytics (CF33-CD19) onCARlytics with CD19 CAR T • Combination of onC
Slide 8: B-Cell Immunotherapies
For personal use only B-Cell Immunotherapies 8
Slide 9: B Cell Based Antibodies Have Distinct Advantages To Existing Treatments
B Cell Based Antibodies Have Distinct Advantages To Existing Treatments For personal use only B cell Vaccines offer a unique opportunity to intervene at multiple points in the immune system and create immune memory which NATURAL B CELL D ERIVED MONOCLONAL enhances durability of response. ANTIBODIES
Slide 10: HER-Vaxx Phase 2 Recruitment Complete
HER-Vaxx Phase 2 Recruitment Complete For personal use only Trial Patients Study Primary Endpoints • Phase 2 • HER-2+++ Randomized • Overall survival • Open label • HER-2++ FISH/CISH +ve HER-Vaxx in combination • Asia • Advance or metastatic with standard of care Secondary Endpoints • Eastern Europe
Slide 11: AACR 2021 Presentation Poster
AACR 2021 Presentation Poster For personal use only 11
Slide 12: AACR 2021 Presentation Highlights
AACR 2021 Presentation Highlights The AACR presentation highlights and presents the following new data: For personal use only • Treatment with HER-Vaxx clearly demonstrates that all patients develop high levels of HER2-specific antibodies early in the treatment protocol. • Analysis of the antibody d
Slide 13: PD1-Vaxx Phase 1 Study Design
PD1-Vaxx Phase 1 Study Design For personal use only MONOTHERAPY DOSE COMBINATION ESCALATION PHASE ESCALATION & EXPANSION Part 1 Part 2 (planned) Indication Non-small cell lung cancer expressing PD-L1 Objectives Safety & Tolerability, Immunogenicity, OBD Monotherapy # Patients Approx. 12-22 Approx. 1
Slide 14: PD1-Vaxx Phase 1 Current Status
PD1-Vaxx Phase 1 Study Design Current Status For personal use only MILESTONES 1st Patient Dosed Cohort 1 Cleared 1st Patient Dosed Cohort 3 Cleared, Cohort 2 Cleared 1st Patient Dosed Cohort 1 Cohort 2 RP2D & Expansion Cohort 3 Opened 30 Nov 2020 Jan 2021 Phase 2 – Expansions Assumption HACKENSACK U
Slide 15: Oncolytic Virus CF33
For personal use only Oncolytic Virus CF33 15
Slide 16: CF33 Mechanism of Action
CF33 Mechanism of Action For personal use only HOW A VIRUS KILLS A CELL Step 1: Step 2: Step 3: Virus enters cell Virus duplicates itself Cell explodes, releasing thousands of brand new virus particles • Direct infection, replication within and cancer cell killing • Viral infection increases local c
Slide 17: CHECKvacc Armed Virus Phase 1 Triple Negative Breast Cancer Study
CHECKvacc “Armed” Virus Phase 1 Triple Negative Breast Cancer Study – GMP Manufacturing Complete For personal use only COHORT | 3-6 PATIENTS IDENTIFY COHORT | 3-6 PATIENTS Recommended Metastatic Triple Phase 2 Dose Negative Breast COHORT | 3-6 PATIENTS (RP2D) RP2D EXPANSION Cancer Based on: 12 PATIE
Slide 18: VAXINIA Phase 1 MAST Study
VAXINIA Phase 1 MAST Study Metastatic Advanced Solid Tumours For personal use only Part 2: VAXINIA + SOC IO* Part 1: VAXINIA Monotherapy Combination Dose Escalation Dose Escalation Dose IDENTIFY Admin IT AND IV COMBINATION IT Administration Dose COHORT | 3-6 COHORT | 3-6 Head & Neck, Admin IT AND IV
Slide 19: The CAR T Solid Tumour Challenge & Imugene's Solution
The CAR T Solid Tumour Challenge & Imugene’s Solution NEW CONCEPT For personal use only Chimeric Antigen Receptor (CAR) T cell therapy has had limited activity in solid tumours, largely due to a lack of selectively and highly expressed surface antigens, such as the blood B cell antigen Utilise OV’s
Slide 20: Four FDA Approved CD19 CAR T's
Four FDA Approved CD19 CAR T’s For personal use only Approved and in-development autologous or allogeneic CD19 CAR Ts can be partnered with Imugene’s onCARlylics for treating solid tumours: 20
Slide 21: CD19 Oncolytic Virus and CAR-T mechanism
CD19 ONCOLYTIC VIRUS — ~~ SoLio 5 CANCER CELL CANCER CELL 1. 2. 3. 4. CD19 ONCOLYTIC VIRUS CD19 ONCOLYTIC VIRUS CAUSES (CD19 CAR-T CELL RECOGNISE CANCER CELL INFECTS SOLID CANCER > THE SOLID CANCER TO GROW > — THECDI9 FLAGS AND > DIES “CD 19 FLAGS" ATTACKS THE CANCER CELL IMUGENE 24
Slide 22: Intellectual Property
Intellectual Property For personal use only FO U NDATION PAT ENT ( 2 0 3 8 ) PCT US2019/033030 Oncolytic virus expressing a CAR T Title cell target and uses thereof Fong, Priceman, Forman, Chen Inventors & Park Assignee City of Hope Primary Date 11 August 2017 International Publication 14 February 2
Slide 23: Milestones
Milestones For personal use only Technology Milestone onCARlytics 1st Patient Dosed Monotherapy Next 12-24 months onCARlytics FDA IND Clearance PD1-Vaxx Combination RP2D onCARlytics GLP Toxicology Study VAXINIA 1st Patient Dosed PD1-Vaxx Expansion combination study FPI HER-Vaxx Phase 2 Final Analysi
Slide 24: Financial Summary
Financial Summary Public Market Overview Share Price Performance (last 6 months) For personal use only Share Price 1 A$0.325 Market Capitalisation 2 A$1.604B Cash equivalents (31 Mar 21) A$29.4M Enterprise Value A$1.575B Top 5 Shareholders (as of May 2021) Mann Family 5.93% Paul Hopper 4.09% Dr Nich
Slide 25: Leslie Chong, Managing Director & CEO
For personal use only Leslie Chong Managing Director & CEO leslie.chong@imugene.com +61 458 040 433